Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression

Pharmacotherapy

Volumn 29, Issue 10, 2009, Pages 1166-1174

  Miller, James T ^a   Collins, Curtis D ^b   Stuckey, Linda J ^b   Luan, Fu L ^c   Englesbe, Michael J ^b   Magee, John C ^b   Park, Jeong M ^b  

^a SINAI GRACE HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cost; Living unrelated donor kidney transplantation; Rabbit antithymocyte globulin; Rejection; Thymoglobulin

Indexed keywords

COTRIMOXAZOLE; CREATININE; CYCLOSPORIN; METHYLPREDNISOLONE; PENTAMIDINE; THYMOCYTE ANTIBODY; THYMOCYTE GLOBULIN ANTIBODY; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DRUG COST; GRAFT FAILURE; HOSPITAL COST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; OUTCOME ASSESSMENT; PNEUMOCYSTOSIS;

ADULT; ANIMALS; ANTILYMPHOCYTE SERUM; COHORT STUDIES; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RABBITS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 70349677177     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.10.1166     Document Type: Article

References (31)

1. U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. 2006 OPTN/SRTR annual report: transplant data 1996-2005. Washington, DC: U.S. Department of Health and Human Services, 2006.
2. ▶2. Matas AJ, Payne WD, Sutherland DE, et al. 2,500 living donor kidney transplants: a single-center experience. Ann Surg 2001;234:149-164
3. ▶3. Campbell SB, Hothersall E, Preston J, et al. Frequency and severity of acute rejection in live- versus cadaveric-donor renal transplants. Transplantation 2003;76:1452-1457
4. ▶4. Wiland AM, Fink JC, Weir M, et al. Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. Transplantation 2004;77:422-425
5. ▶5. Fuller TF, Feng S, Brennan TV, Tomlanovich S, Bostrom A, Freise CE. Increased rejection in living unrelated versus living related kidney transplants does not affect short-term function and survival. Transplantation 2004;78:1030-1035
6. ▶6. Long DG, Vernon WB, Yanover MJ. Increased acute rejection episodes among recipients of living unrelated donor compared with cadaver and living related donor renal transplants. Transplant Proc 2002;34:1673-1674
7. ▶7. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993;55:752-756
8. ▶8. Matas AJ, Gillingham K, Humar A, Dunn DL, Sutherland DE, Najarian JS. Immunologic and nonimmunologic factors: different risks for cadaver and living donor transplantation. Transplantation 1999;69:54-58
9. ▶9. Knight RJ, Burrows L, Bodian C. The influence of acute rejection on long-term renal allograft survival: a comparison of living and cadaveric donor transplantation. Transplantation 2001;72:69-76.
10. ▶10. Khan S, Tighiouart H, Kalra A, Raman G, Rohrer RJ, Pereira BJG. Resource utilization among kidney transplant recipients. Kidney Int 2003;64:657-664 (Pubitemid 36871939)
11. ▶11. Hagenmeyer EG, Häussler B, Hempel E, et al. Resource use and treatment costs after kidney transplantation: impact of demographic factors, comorbidities, and complications. Transplantation 2004;77:1545-1550
12. ▶12. Mourad G, Garrigue V, Squifflet JP, et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 2001;72:1050-1055 (Pubitemid 32924076)
13. ▶13. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999;67:1011-1018 (Pubitemid 29200852)
14. ▶14. Brennan, DC, Daller JA, Lake KD, Cibrik D, Del Castillo D, for the Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006;355:1967-1977
15. ▶15. Charpenter B, Rostaing L, Berthoux F, et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 2003;75:844-851
16. Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002;13:769-772 (Pubitemid 34183944)
17. ▶17. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and transplantation. Transplantation 2003;76:1289-1293
18. ▶18. Annesley TM, Clayton L. Simple extraction protocol for analysis of immunosuppressant drugs in whole blood. Clin Chem 2004;50(10):1845-1848
19. ▶19. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999;55:713-723 (Pubitemid 29082898)
20. U.S. Department of Labor, Bureau of Labor Statistics. Consumer price indexes. Available from http://www.bls.gov/cpi. Accessed August 1, 2008.
21. ▶21. Hardinger KL, Schnitzler MA, Koch MJ, et al. Thymoglobulin induction is safe and effective in live-donor renal transplantation: a single center experience. Transplantation 2006;81:1285-1289
22. Gaber AO, Schnitzler M, Willoughby L, Stirneman P, for the TAILOR Investigators. Thymoglobulin induction in living donor renal transplant recipients: report from TAILOR registry [abstract]. Am J Transplant 2006;6(suppl 2):293.
23. Gelone D, Cibrik D, Volger S, Leichtman A, Lake K. Comparative efficacy and safety of low dose valganciclovir vs. oral ganciclovir for the prevention of cytomegalovirus disease in renal allograft recipients [abstract]. Am J Transplant 2003;3(suppl 5):511.
24. ▶24. Akalin E, Bromberg JS, Sehgal V, Ames S, Murphy B. Decreased incidence of cytomegalovirus infection in Thymoglobulin-treated transplant patients with 6 months of valganciclovir prophylaxis. Am J Transplant 2004;4:148-149
25. ▶25. Crompton JA, Somerville T, Smith L, et al. Lack of economic benefit with basiliximab induction in living related donor adult renal transplant recipients. Pharmacotherapy 2003;23:443-450
26. ▶26. Silva HT Jr, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007;7(3):595-608.
27. ▶27. Thorban S, Schwarznau A, Hüser N, Stangl M. Efficacy of conventional immunosuppressive therapy in related and unrelated living renal transplantation. Clin Transplant 2006;20:284-288
28. Fleming T, ed. Drug topics red book. Montvale, NJ: Thomson PDR, 2006.
29. ▶29. Agha IA, Rueda J, Alvarez A, et al. Short course induction immunosuppression with Thymoglobulin for renal transplant recipients. Transplantation 2002;73:473-475 (Pubitemid 34174301)
30. ▶30. Stevens RB, Mercer DF, Grant WJ, et al. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. Transplantation 2008;85:1391-1399
31. ▶31. Gurk-Turner C, Airee R, Philosophe D, Kukuruga D, Drachenberg C, Haririan A. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. Transplantation 2008;85:1425-1430